VIZZ Breaks Into Market With $1.6M Revenue in Debut Quarter as LENZ Expands Presbyopia Treatment Solutions

LENZ Therapeutics has achieved significant commercial momentum following the market entry of VIZZ, its acetylcholine-based eye drop formulation designed to address presbyopia, a widespread vision condition affecting approximately 128 million Americans. The company’s quarterly performance data underscores rapid adoption rates in the early stages of market penetration.

Strong Prescription Growth Signals Market Demand

During the fourth quarter of 2025, VIZZ captured considerable physician engagement with more than 20,000 prescriptions fulfilled across the U.S. market. The product’s reach extended to over 6,500 Eye Care Professionals, with a striking 55% repeat prescription rate during the same period—a metric suggesting meaningful clinical confidence and patient satisfaction with the presbyopia treatment approach.

Since hitting shelves last October and achieving widespread market availability by mid-November, VIZZ has established itself as the only FDA-approved acetylcholine-based solution in its category, following approval authorization in August 2025. The financial results reflect this momentum: net product revenue reached approximately $1.6 million in Q4 2025.

Understanding the Market Opportunity

Presbyopia represents an age-related optical challenge wherein the eye’s lens gradually stiffens, diminishing its capacity to accommodate near-vision focus. This condition manifests as progressive blurriness when viewing objects at close range—a nearly universal experience for aging populations and a significant quality-of-life concern for millions seeking functional vision solutions.

International Expansion Accelerates

LENZ has fortified its commercial infrastructure beyond domestic markets through four strategic partnerships. The company has established distribution agreements with CORXEL Pharmaceuticals for mainland China operations, Lotus Pharmaceutical for South Korean and select Southeast Asian territories, Laboratoires Théa managing Canadian distribution, and Lunatus serving Middle Eastern markets. The Lunatus partnership, finalized in early January, represents the most recent milestone in the company’s global expansion of its presbyopia treatment initiative.

The organization plans to roll out direct-to-consumer marketing efforts during the current quarter, signaling a shift toward broader consumer awareness alongside its established healthcare provider engagement strategy.

Market Position and Trading Activity

LENZ concluded recent trading at $16.31, reflecting a 3.20% decline, with overnight sessions showing modest recovery at $16.33, up 0.12%.